Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Moleculin Biotech ( (MBRX) ) is now available.
On December 21, 2025, Moleculin Biotech, Inc. amended its Series E, F and G warrants, reducing the exercise price to $3.90 per share, removing certain anti-dilution and price-adjustment provisions in the Series E and F warrants, and revising the Black Scholes Value definition, changes that allowed reclassification of affected warrants from liabilities to equity. The company has been working to regain compliance with Nasdaq’s minimum stockholders’ equity requirement after a May 23, 2025 deficiency notice and a November 20, 2025 delisting determination, and by December 2025 it completed a $6.8 million warrant inducement financing, raised about $1.1 million through its at-the-market offering, and executed the warrant amendments, actions that moved it from a $26.9 million stockholders’ deficit as of September 30, 2025 to more than $10 million in stockholders’ equity ahead of a scheduled Nasdaq hearing on January 20, 2026.
The most recent analyst rating on (MBRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a clinical-stage biopharmaceutical company that develops innovative oncology drug candidates, focusing on small-molecule therapies aimed at treating highly resistant tumors and hard-to-treat cancers, and is listed on The Nasdaq Stock Market LLC.
Average Trading Volume: 297,609
Technical Sentiment Signal: Sell
Current Market Cap: $8.06M
For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.